FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313365080> ?p ?o ?g. }

• W4313365080 endingPage "e003032" @default.
• W4313365080 startingPage "e003032" @default.
• W4313365080 abstract "To present longitudinal data from the Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND) in Japan.In this multicenter, prospective, observational cohort study, patients with type 2 diabetes mellitus (T2DM) newly initiated on monotherapy were followed up for 2 years. Primary outcomes included changes in treatment pattern over time, target hemoglobin A1c (HbA1c) attainment and treatment satisfaction per Oral Hypoglycaemic Agent Questionnaire (OHA-Q).Among 1474 enrolled patients (male, 62.1%; mean age, 59.7 years; HbA1c, 8.08%), the oral antidiabetic drug (OAD) monotherapy prescription rate decreased to 47.2% and that of 2 and ≥3 OADs increased to 14.8% and 5.4% at 24 months, respectively. Switch/add-on OAD was associated with higher HbA1c and body mass index (BMI), baseline OAD being non-dipeptidyl peptidase-4 inhibitor (DPP-4i)/non-sodium glucose cotransporter-2 inhibitor (SGLT2i), diabetes complications, no comorbidities and consulting a diabetes specialist. The mean (SD) HbA1c (%) was 6.73 (0.85) at 24 months. Higher HbA1c, diabetes complications, cardiovascular disease, being employed, no hypertension and younger treating physician were associated with ≥2 OAD classes prescription or target HbA1c non-attainment at 24 months. OHA-Q subscale scores were significantly higher in patients achieving (vs not achieving) target HbA1c and in those continuing monotherapy (vs combination therapy). Baseline age (<65 years), sex (female), HbA1c, alcohol use, use of non-‍DPP-4i OADs or non-T2DM drugs, diabetes complications and cardiovascular disease had a significant negative impact, while EuroQol five-dimensional five-level and Summary of Diabetes Self-Care Activities-specific diet scores, BMI and unemployment had a significant positive impact on OHA-Q scores at 24 months.Primary outcomes show real-world treatment patterns and glycemic control over 2 years in patients with T2DM newly initiated on OAD monotherapy in Japan. Key factors associated with durability of initial monotherapy, target achievement or treatment satisfaction included baseline HbA1c, comorbidity and initial OAD choice." @default.
• W4313365080 created "2023-01-06" @default.
• W4313365080 creator A5009147715 @default.
• W4313365080 creator A5025304234 @default.
• W4313365080 creator A5037081977 @default.
• W4313365080 creator A5037246488 @default.
• W4313365080 creator A5040548657 @default.
• W4313365080 creator A5040795360 @default.
• W4313365080 creator A5043895658 @default.
• W4313365080 creator A5044405976 @default.
• W4313365080 date "2022-12-01" @default.
• W4313365080 modified "2023-10-16" @default.
• W4313365080 title "Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND)" @default.
• W4313365080 cites W1607858358 @default.
• W4313365080 cites W1966067906 @default.
• W4313365080 cites W1996638018 @default.
• W4313365080 cites W1997967476 @default.
• W4313365080 cites W1998401806 @default.
• W4313365080 cites W2053939314 @default.
• W4313365080 cites W2079597412 @default.
• W4313365080 cites W2113758823 @default.
• W4313365080 cites W2149435665 @default.
• W4313365080 cites W2150722215 @default.
• W4313365080 cites W2150959326 @default.
• W4313365080 cites W2165825148 @default.
• W4313365080 cites W2338042410 @default.
• W4313365080 cites W2475311184 @default.
• W4313365080 cites W2567000504 @default.
• W4313365080 cites W2588363830 @default.
• W4313365080 cites W2592996796 @default.
• W4313365080 cites W2611496397 @default.
• W4313365080 cites W2738595939 @default.
• W4313365080 cites W2801347411 @default.
• W4313365080 cites W2986435123 @default.
• W4313365080 cites W3005763315 @default.
• W4313365080 cites W3026905052 @default.
• W4313365080 cites W3044697752 @default.
• W4313365080 cites W3081975532 @default.
• W4313365080 cites W3086213814 @default.
• W4313365080 cites W3099282933 @default.
• W4313365080 cites W3183379942 @default.
• W4313365080 cites W3202796626 @default.
• W4313365080 cites W3216012020 @default.
• W4313365080 cites W4200197703 @default.
• W4313365080 cites W4200439235 @default.
• W4313365080 cites W4213324688 @default.
• W4313365080 cites W4221134792 @default.
• W4313365080 cites W74305558 @default.
• W4313365080 doi "https://doi.org/10.1136/bmjdrc-2022-003032" @default.
• W4313365080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585033" @default.
• W4313365080 hasPublicationYear "2022" @default.
• W4313365080 type Work @default.
• W4313365080 citedByCount "2" @default.
• W4313365080 countsByYear W43133650802023 @default.
• W4313365080 crossrefType "journal-article" @default.
• W4313365080 hasAuthorship W4313365080A5009147715 @default.
• W4313365080 hasAuthorship W4313365080A5025304234 @default.
• W4313365080 hasAuthorship W4313365080A5037081977 @default.
• W4313365080 hasAuthorship W4313365080A5037246488 @default.
• W4313365080 hasAuthorship W4313365080A5040548657 @default.
• W4313365080 hasAuthorship W4313365080A5040795360 @default.
• W4313365080 hasAuthorship W4313365080A5043895658 @default.
• W4313365080 hasAuthorship W4313365080A5044405976 @default.
• W4313365080 hasBestOaLocation W43133650801 @default.
• W4313365080 hasConcept C126322002 @default.
• W4313365080 hasConcept C134018914 @default.
• W4313365080 hasConcept C188816634 @default.
• W4313365080 hasConcept C23131810 @default.
• W4313365080 hasConcept C2426938 @default.
• W4313365080 hasConcept C2776999253 @default.
• W4313365080 hasConcept C2777180221 @default.
• W4313365080 hasConcept C2780221984 @default.
• W4313365080 hasConcept C2910068830 @default.
• W4313365080 hasConcept C555293320 @default.
• W4313365080 hasConcept C71924100 @default.
• W4313365080 hasConcept C98274493 @default.
• W4313365080 hasConceptScore W4313365080C126322002 @default.
• W4313365080 hasConceptScore W4313365080C134018914 @default.
• W4313365080 hasConceptScore W4313365080C188816634 @default.
• W4313365080 hasConceptScore W4313365080C23131810 @default.
• W4313365080 hasConceptScore W4313365080C2426938 @default.
• W4313365080 hasConceptScore W4313365080C2776999253 @default.
• W4313365080 hasConceptScore W4313365080C2777180221 @default.
• W4313365080 hasConceptScore W4313365080C2780221984 @default.
• W4313365080 hasConceptScore W4313365080C2910068830 @default.
• W4313365080 hasConceptScore W4313365080C555293320 @default.
• W4313365080 hasConceptScore W4313365080C71924100 @default.
• W4313365080 hasConceptScore W4313365080C98274493 @default.
• W4313365080 hasFunder F4320333376 @default.
• W4313365080 hasIssue "6" @default.
• W4313365080 hasLocation W43133650801 @default.
• W4313365080 hasLocation W43133650802 @default.
• W4313365080 hasLocation W43133650803 @default.
• W4313365080 hasOpenAccess W4313365080 @default.
• W4313365080 hasPrimaryLocation W43133650801 @default.
• W4313365080 hasRelatedWork W1563850031 @default.
• W4313365080 hasRelatedWork W2045367862 @default.
• W4313365080 hasRelatedWork W2164009748 @default.

• next